[go: up one dir, main page]

WO2006013546A3 - Process for the preparation of pure galantamine - Google Patents

Process for the preparation of pure galantamine Download PDF

Info

Publication number
WO2006013546A3
WO2006013546A3 PCT/IB2005/052553 IB2005052553W WO2006013546A3 WO 2006013546 A3 WO2006013546 A3 WO 2006013546A3 IB 2005052553 W IB2005052553 W IB 2005052553W WO 2006013546 A3 WO2006013546 A3 WO 2006013546A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
galantamine
pure
pure galantamine
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/052553
Other languages
French (fr)
Other versions
WO2006013546A2 (en
Inventor
Saswata Lahiri
Mohan Prasad
Nitin Maheshwari
Yatendra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of WO2006013546A2 publication Critical patent/WO2006013546A2/en
Publication of WO2006013546A3 publication Critical patent/WO2006013546A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to processes for the preparation of pure galantamine or pharmaceutically acceptable salts thereof. More particularly, it relates to the preparation of pure galantamine hy­drobromide. The invention also relates to pharmaceutical compositions that include the pure galantamine or pharmaceutically acceptable salts thereof and use of said compositions for treating Alzheimer's disease, dementia, mania, fatigue syndrome, and schizophrenia.
PCT/IB2005/052553 2004-07-28 2005-07-28 Process for the preparation of pure galantamine Ceased WO2006013546A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1393/DEL/2004 2004-07-28
IN1393DE2004 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006013546A2 WO2006013546A2 (en) 2006-02-09
WO2006013546A3 true WO2006013546A3 (en) 2006-05-11

Family

ID=35285287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/052553 Ceased WO2006013546A2 (en) 2004-07-28 2005-07-28 Process for the preparation of pure galantamine

Country Status (1)

Country Link
WO (1) WO2006013546A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102050826B (en) * 2010-12-21 2012-11-14 浙江工业大学 Method for separating galanthamine
CN104177368B (en) * 2014-05-27 2016-06-08 天津梅花医药有限公司 A kind of galanthamine hydrobromide compound, preparation method and pharmaceutical composition thereof
CN116903633B (en) * 2022-10-10 2025-11-18 福建医科大学 Preparation method of high-purity gelsemin and its pharmaceutically acceptable salt based on chiral organic acid separation

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012692A1 (en) * 1994-10-21 1996-05-02 Waldheim Pharmazeutika Gesellschaft M.B.H. PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINE
AT401058B (en) * 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Process for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro(3a, 3, 2- ef)(2)benzazepine
US5877172A (en) * 1995-03-17 1999-03-02 Lts Lohmann Therapie-Systeme Gmbh Process for isolating galanthamine
WO2000030446A1 (en) * 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
US6087495A (en) * 1996-01-04 2000-07-11 Janssen Pharmaceutica, N.V. Process for the preparation of galanthamine
US6346618B1 (en) * 1996-05-24 2002-02-12 Janssen Pharmaceutica N.V. Optical resolution of narwedine-type compounds
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012692A1 (en) * 1994-10-21 1996-05-02 Waldheim Pharmazeutika Gesellschaft M.B.H. PROCESS FOR PRODUCING DERIVATIVES OF 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINE
AT401058B (en) * 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Process for the preparation of derivatives of 4a, 5, 9, 10, 11, 12-hexahydro-6H-benzofuro(3a, 3, 2- ef)(2)benzazepine
US5877172A (en) * 1995-03-17 1999-03-02 Lts Lohmann Therapie-Systeme Gmbh Process for isolating galanthamine
US6087495A (en) * 1996-01-04 2000-07-11 Janssen Pharmaceutica, N.V. Process for the preparation of galanthamine
US6346618B1 (en) * 1996-05-24 2002-02-12 Janssen Pharmaceutica N.V. Optical resolution of narwedine-type compounds
WO2000030446A1 (en) * 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
WO2004002402A2 (en) * 2002-05-21 2004-01-08 Nastech Pharmaceutical Company Inc. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040097484A1 (en) * 2002-11-14 2004-05-20 Marc Cantillion Once a day galantamine pharmaceutical compositions and methods of use
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
WO2005065661A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galanthamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMETANI T ET AL: "THE OPTICAL RESOLUTION OF ( )-GALANTHAMINE", HETEROCYCLES, vol. 4, no. 6, 1976, pages 1111 - 1114, XP000603575, ISSN: 0385-5414 *
SZEWCZYK, WILSON, LEWIN, CAROLL, J. HETEROCYCLIC CHEM., vol. 32, 1995, pages 195 - 199, XP002354925 *

Also Published As

Publication number Publication date
WO2006013546A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
WO2004074232A8 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
WO2006001877A3 (en) Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL188752A0 (en) Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
WO2007058805A3 (en) Compositions and methods for treating cns disorders
WO2006013546A3 (en) Process for the preparation of pure galantamine
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2007017146A3 (en) Use of collismycin and derivatives thereof as oxidative stress inhibitors
WO2007063428A3 (en) Pharmaceutical compositions comprising carboxyalkylsulfonic acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1277/DELNP/2007

Country of ref document: IN

122 Ep: pct application non-entry in european phase